ProJenX Alternatives & Competitors
12 companies similar to ProJenX — ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhi...
Companies similar to ProJenX
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...
Mclean, United States
Sudo Biosciences
Developing precision TYK2 therapeutics.
Carmel, United States
Sling Therapeutics
Focused on late-stage development of an oral small molecule for the treatment of thyroid e...
Ann Arbor, United States
Neumora
Pioneering a new era of medicines for brain diseases
Watertown, United States
Rival Readout
Competing with ProJenX? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
NeuroSense Therapeutics
Creatively and diligently moving fast towards an effective treatment for people with ALS.
Cambridge, United States
Vertero Therapeutics, Inc.
Pioneering science beyond the brain to treat neurodegenerative diseases at their source
Woburn, United States
Chance Pharmaceuticals 畅溪制药
A clinical-stage biotech company focusing on discovering, developing and commercializing i...
China
BioAge Labs
We are harnessing the biology of human aging to develop novel targets and therapies for me...
Emeryville, United States
Zenas BioPharma
Enabling patients with autoimmune diseases to reimagine life
Waltham, United States
Inventiva Pharma
A clinical-stage biopharmaceutical company focused on the development of oral small molecu...
France
OrsoBio
Advancing first-in-class therapies to restore energy homeostasis
Palo Alto, United States
Spinogenix, Inc.
Developing a new class of therapeutics for neurodegenerative and psychiatric diseases
Los Angeles, United State...
About ProJenX
ProJenX, founded in 2021, is a clinical-stage biotechnology company based in the United States. Specializing in targeted, brain-penetrant treatments for neurodegenerative diseases, it focuses initially on ALS with its lead therapy candidate, prosetin. Emerging from a collaboration with Project ALS and Columbia Universi...
Drug Development for ALS, Clinical Trial Execution, Research and Development of Neurodegenerative Therapies, Discovery and Preclinical Testing of Kinase Inhibitors
Individuals with Amyotrophic Lateral Sclerosis (ALS), Healthcare Providers in Neurology, Research Institutions Focusing on Neuroscience, Neurodegenerative Disease Community
Clinical-stage Biotechnology, Neurodegenerative Diseases, ALS Therapy, Brain-penetrant Therapies, MAPK Therapeutics, Motor Neuron Degenerative Pathways, Small Molecule Therapeutics, Patient-specific Discovery Platform, Neuroscience Medicines, Prosetin Development, Research Collaboration, Biopharmaceutical Innovation, Neurology
B2B, B2D
Licensing, Performance Based, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around ProJenX: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at ProJenX on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
